Sumitomo Mitsui Trust Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Sumitomo Mitsui Trust Group's NBIX Position: Q3 2026 in Review
Sumitomo Mitsui Trust Group reduced its Neurocrine Biosciences (NBIX) stake by 2.1% in Q3 2026, selling an estimated $717K and leaving 211,026 shares worth $29.9M. The position accounts for 0.02% of the portfolio, ranked #555.
Sumitomo Mitsui Trust Group first reported a position in NBIX in Q4 2019 and has held it in 28 quarters since. The position peaked at $52M in Q2 2020. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Sumitomo Mitsui Trust Group held 211,026 shares of Neurocrine Biosciences worth $29.9M as of Q3 2026.
- Sumitomo Mitsui Trust Group sold 4,462 Neurocrine Biosciences shares in Q3 2026, an estimated $717K.
- Neurocrine Biosciences made up 0.02% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #555 holding.
- Sumitomo Mitsui Trust Group first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 28 quarters since.
- Sumitomo Mitsui Trust Group's Neurocrine Biosciences position peaked at $52M in Q2 2020.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.